DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,441,548 | -27.4% | 404,843 | -29.8% | 1.08% | -23.9% |
| Q2 2023 | $138,335,760 | -8.9% | 576,399 | -4.3% | 1.42% | -11.4% |
| Q1 2023 | $151,767,650 | -9.6% | 602,157 | -4.8% | 1.60% | -12.3% |
| Q4 2022 | $167,855,589 | -63.4% | 632,415 | -64.3% | 1.83% | -59.7% |
| Q3 2022 | $458,053,000 | -16.9% | 1,773,404 | -18.4% | 4.54% | -11.8% |
| Q2 2022 | $551,241,000 | -14.0% | 2,174,351 | -0.5% | 5.14% | +6.2% |
| Q1 2022 | $640,869,000 | +1.5% | 2,184,805 | +13.8% | 4.84% | +14.7% |
| Q4 2021 | $631,489,000 | +35.6% | 1,919,361 | +25.5% | 4.22% | +31.5% |
| Q3 2021 | $465,564,000 | +14.7% | 1,529,248 | +1.1% | 3.21% | +16.1% |
| Q2 2021 | $406,005,000 | +16.4% | 1,512,911 | -2.4% | 2.76% | +14.0% |
| Q1 2021 | $348,756,000 | -11.0% | 1,549,475 | -12.1% | 2.42% | -10.8% |
| Q4 2020 | $391,644,000 | -27.5% | 1,763,050 | -29.7% | 2.72% | -27.3% |
| Q3 2020 | $540,260,000 | +10.3% | 2,508,988 | -9.4% | 3.74% | -2.4% |
| Q2 2020 | $489,819,000 | +3.5% | 2,770,000 | -19.0% | 3.83% | -15.9% |
| Q1 2020 | $473,362,000 | -12.8% | 3,420,000 | -3.3% | 4.55% | +7.1% |
| Q4 2019 | $542,759,000 | -3.6% | 3,536,350 | -9.3% | 4.25% | -13.6% |
| Q3 2019 | $562,941,000 | -5.0% | 3,897,671 | -6.0% | 4.92% | -7.0% |
| Q2 2019 | $592,785,000 | -3.1% | 4,147,671 | -10.5% | 5.29% | -5.8% |
| Q1 2019 | $611,913,000 | +29.1% | 4,635,000 | +0.9% | 5.62% | +25.0% |
| Q4 2018 | $473,836,000 | +18.7% | 4,595,000 | +25.0% | 4.50% | +26.9% |
| Q3 2018 | $399,326,000 | +5.8% | 3,675,000 | -3.9% | 3.54% | -2.2% |
| Q2 2018 | $377,451,000 | +5.6% | 3,825,000 | +4.8% | 3.62% | +1.9% |
| Q1 2018 | $357,372,000 | -6.5% | 3,650,000 | -11.4% | 3.56% | -2.2% |
| Q4 2017 | $382,172,000 | +8.2% | 4,117,348 | 0.0% | 3.64% | +4.0% |
| Q3 2017 | $353,186,000 | +55.4% | 4,117,348 | +52.9% | 3.49% | +50.7% |
| Q2 2017 | $227,207,000 | -1.3% | 2,692,348 | 0.0% | 2.32% | -5.2% |
| Q1 2017 | $230,277,000 | +40.7% | 2,692,348 | +28.1% | 2.44% | +22.7% |
| Q4 2016 | $163,647,000 | -23.2% | 2,102,348 | -22.7% | 1.99% | -19.3% |
| Q3 2016 | $213,093,000 | -37.6% | 2,718,364 | -19.5% | 2.47% | -36.8% |
| Q2 2016 | $341,255,000 | +6.5% | 3,378,763 | 0.0% | 3.91% | +7.2% |
| Q1 2016 | $320,509,000 | +3.2% | 3,378,763 | +1.0% | 3.64% | +3.1% |
| Q4 2015 | $310,633,000 | -3.9% | 3,344,460 | -11.9% | 3.53% | -1.7% |
| Q3 2015 | $323,326,000 | +2.3% | 3,794,460 | +2.7% | 3.59% | +10.9% |
| Q2 2015 | $316,209,000 | +55.5% | 3,694,460 | +54.3% | 3.24% | +53.1% |
| Q1 2015 | $203,290,000 | -2.2% | 2,394,460 | -1.3% | 2.12% | -4.8% |
| Q4 2014 | $207,895,000 | +15.7% | 2,425,558 | +2.6% | 2.22% | +15.5% |
| Q3 2014 | $179,621,000 | +55.5% | 2,364,058 | +61.1% | 1.92% | +60.4% |
| Q2 2014 | $115,501,000 | +60.4% | 1,467,058 | +52.8% | 1.20% | +47.1% |
| Q1 2014 | $72,004,000 | -16.5% | 960,058 | -14.1% | 0.82% | -14.6% |
| Q4 2013 | $86,236,000 | +11.4% | 1,117,052 | 0.0% | 0.96% | +1.2% |
| Q3 2013 | $77,434,000 | +9.5% | 1,117,052 | 0.0% | 0.94% | +4.7% |
| Q2 2013 | $70,709,000 | – | 1,117,052 | – | 0.90% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |